At the news
? BULLISHIMPACT 7/10 25-NSE filed Jul 13, 2026 at 09:19 ET
Esperion Therapeutics has been delisted from Nasdaq following its acquisition by ArchiMed (via Essence Parent Inc.) for $3.16 per share plus CVRs. The 25-NSE filing formalizes the removal of the company's common stock from listing and SEC registration, effective July 13, 2026. This is the final procedural step in the going-private transaction, and the stock will no longer trade on Nasdaq.
- Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one CVR per share representing up to $100M in aggregate milestone payments.
- The 25-NSE filing formalizes the removal of Esperion's common stock from listing and registration on Nasdaq, effective July 13, 2026.
- The delisting follows a change of control, board replacement, and termination of the prior credit agreement with new debt financing from BioPharma Credit.
- The filing is made under Rule 17 CFR 240.12d2-2(a)(3), which covers securities that have been redeemed, retired, or matured.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access